Vera Therapeutics, (id:6650 VERA)
48.31 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:25:24 PM)
Exchange closed, opens in 1 day 11 hours
About Vera Therapeutics,
Market Capitalization 3.10B
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Headquarters (address) |
8000 Marina Boulevard Brisbane 94005 CA United States |
| Phone | 650 770 0077 |
| Website | https://veratx.com |
| Employees | 72 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | VERA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 12.28 - 51.61 |
| Market Capitalization | 3.10B |
| P/E trailing | -21.47 |
| P/E forward | -15.76 |
| Price/Book | 9.33 |
| Beta | 1.02 |
| EPS | -2.59 |
| EPS United States (ID:6, base:3403) | 24.22 |